PMID- 22052584
OWN - NLM
STAT- MEDLINE
DCOM- 20120313
LR  - 20151119
IS  - 2151-4658 (Electronic)
IS  - 2151-464X (Linking)
VI  - 64
IP  - 2
DP  - 2012 Feb
TI  - Women with gout: efficacy and safety of urate-lowering with febuxostat and 
      allopurinol.
PG  - 256-61
LID - 10.1002/acr.20680 [doi]
AB  - OBJECTIVE: To compare the characteristics of female versus male gout patients and 
      assess urate-lowering efficacy and safety of febuxostat or allopurinol treatment 
      in women with gout. METHODS: This was a retrospective analysis of 4,101 
      hyperuricemic (serum urate [sUA] level >/=8.0 mg/dl) gout subjects enrolled in 3 
      phase III comparative trials and randomized to receive placebo, febuxostat (40 
      mg, 80 mg, 120 mg, or 240 mg daily), or allopurinol (100 mg, 200 mg, or 300 mg 
      daily, based on renal function). Baseline demographics and characteristics were 
      summarized and compared between female and male subjects. Urate-lowering 
      efficacy, which was defined as the proportion of subjects with sUA levels <6.0 
      mg/dl at final visit, was assessed for all subjects and, among women, according 
      to baseline renal function. RESULTS: Female gout subjects (n = 226) were older 
      with significantly higher rates of obesity and metabolic and cardiovascular 
      comorbidities than their male counterparts. The percentage of female subjects 
      with sUA levels <6.0 mg/dl at final visit was 0% in the placebo group, 54.3%, 
      85.1%, 81.0%, and 100.0% in the febuxostat 40 mg, 80 mg, 120 mg, and 240 mg 
      groups, respectively, and 45.9% in the allopurinol group. Similar patterns of 
      urate-lowering efficacy rates were observed when stratified by renal function. 
      Among all the female subjects, febuxostat 80 mg was significantly more 
      efficacious than allopurinol (P < 0.001). Rates of adverse events (AEs) were low. 
      The most frequently reported AEs were upper respiratory tract infections, 
      musculoskeletal/connective tissue disorders, and diarrhea. CONCLUSION: These data 
      suggest that febuxostat 80 mg may be more efficacious than commonly prescribed 
      doses of allopurinol in female gout subjects with high rates of comorbidities.
CI  - Copyright (c) 2012 by the American College of Rheumatology.
FAU - Chohan, Saima
AU  - Chohan S
AD  - University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA. 
      schohan@medicine.bsd.uchicago.edu
FAU - Becker, Michael A
AU  - Becker MA
FAU - MacDonald, Patricia A
AU  - MacDonald PA
FAU - Chefo, Solomon
AU  - Chefo S
FAU - Jackson, Robert L
AU  - Jackson RL
LA  - eng
SI  - ClinicalTrials.gov/NCT00102440
SI  - ClinicalTrials.gov/NCT00174915
SI  - ClinicalTrials.gov/NCT00430248
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arthritis Care Res (Hoboken)
JT  - Arthritis care & research
JID - 101518086
RN  - 0 (Gout Suppressants)
RN  - 0 (Thiazoles)
RN  - 101V0R1N2E (Febuxostat)
RN  - 268B43MJ25 (Uric Acid)
RN  - 63CZ7GJN5I (Allopurinol)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Allopurinol/*therapeutic use
MH  - Cardiovascular Diseases/epidemiology
MH  - Comorbidity
MH  - Febuxostat
MH  - Female
MH  - Gout/blood/*drug therapy/epidemiology
MH  - Gout Suppressants/*therapeutic use
MH  - Humans
MH  - Hyperuricemia/blood/*drug therapy
MH  - Illinois/epidemiology
MH  - Male
MH  - Metabolic Diseases/epidemiology
MH  - Middle Aged
MH  - Obesity/epidemiology
MH  - Retrospective Studies
MH  - Sex Factors
MH  - Thiazoles/*therapeutic use
MH  - Treatment Outcome
MH  - Uric Acid/blood
MH  - Young Adult
EDAT- 2011/11/05 06:00
MHDA- 2012/03/14 06:00
CRDT- 2011/11/05 06:00
PHST- 2011/11/05 06:00 [entrez]
PHST- 2011/11/05 06:00 [pubmed]
PHST- 2012/03/14 06:00 [medline]
AID - 10.1002/acr.20680 [doi]
PST - ppublish
SO  - Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680.